NC-LENOVO
28.2.2024 15:01:36 CET | Business Wire | Press release
Lenovo (HKSE: 992) (ADR: LNVGY) is rolling out a new solution to help customers extend the lifecycle of their devices with cost-efficient IT choices for a more sustainable future. Through Lenovo Certified Refurbished, organizations can deploy refurbished PCs that cater to their different computing needs and help manage their IT carbon footprint. Lenovo TruScale Device as a Service (DaaS) customers will also have more options to optimize their IT mix according to their unique economic and business needs, and with circularity in mind. Only Lenovo and accredited partners will offer the Lenovo certification, guaranteeing industry-leading quality devices that businesses can depend on.
“Environmental sustainability is a leading concern for businesses of every size, in every sector,” said Claudia Contreras, Executive Director of Global Sustainability Services for Lenovo. “Lenovo Certified Refurbished extends the lifecycle of our technology to improve ROI and help reduce waste, offering a solution that provides customers a purchase option to help support a more sustainable future. Certified Refurbished will help reduce e-waste, give devices new life, and positively contribute to the circular economy.”
Refurbishment, reuse, and recycling are key concepts in the circular economy, a resource and consumption system that helps mitigate waste. Lenovo is committed to implementing circular practices at every stage of the IT lifecycle, and as a leading global PC manufacturer, is uniquely qualified to help customers meet sustainability goals and embrace the benefits of circularity with confidence. Through the Lenovo 360 Circle community, channel partners are also aligned with collaborative actions to drive circular outcomes for customers and build a more sustainable future.
Lenovo’s 2023 Global Study of CIOs found that 60% of CIOs are turning towards as a Service (aaS) offerings for their tech stacks, including for sustainability management, and 62% said they find it challenging for their organization to reach sustainability goals. Outcome-based consumption models like Lenovo TruScale DaaS help businesses efficiently manage services, cost reduction, and waste reduction through a single source with the flexibility to scale as needed.
“Along with unified program management and streamlined financing, Lenovo TruScale DaaS offers lifecycle transformation approaches – including IT carbon footprint management and e-waste reduction – that help drive circularity and move customers closer to their sustainability goals while also helping to improve productivity and cost considerations. We’re excited to extend TruScale DaaS benefits to include options like Lenovo Certified Refurbished and help make IT circularity more achievable for customers,” said Anupam Garg, Lenovo Digital Workplace Solutions Offering Development leader.
Lenovo Certified Refurbished PCs undergo comprehensive data sanitization; expert testing to meet Lenovo’s high quality, security, and performance standards; and transparent, consistent quality grading. Access to Lenovo’s global support network provides added assurance that there is no compromise on security safeguards or PC performance, and that the refurbished devices will have a productive operational life with up to three years of standard warranty (with the option to upgrade). Lenovo Certified Refurbished PCs can help customers lower technology outlays while retaining a high level of performance and functionality, and refurbished devices may open a wider pool of options for budget-conscious organizations.
Lenovo Certified Refurbished PCs will be available initially in Denmark, France, Germany, and the U.K., with a planned global rollout. Lenovo Certified Refurbished is the latest in a series of Lenovo offerings that aid customers in their sustainability journeys. Learn more about Lenovo’s Sustainability Solutions.
About Lenovo
Lenovo is a US$62 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, employing 77,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company by further expanding into growth areas that fuel the advancement of ‘New IT’ technologies (client, edge, cloud, network, and intelligence) including server, storage, mobile, software, solutions, and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992)(ADR: LNVGY). To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub.
LENOVO and TRUSCALE are trademarks of Lenovo. ©2024 Lenovo. All rights reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228104727/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom